Eisai Co., Ltd. and Biogen Inc. announced that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK) is now available in the U.S. for initiation therapy for early… read more.
Abbott announced it has received CE Mark for the Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with… read more.
Royal Philips and Imricor Medical Systems announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration combines Philips’ 1.5T MRI platform… read more.
AbbVie announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) for subcutaneous (SC) induction for the treatment of adult… read more.
Eli Lilly and Company announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound (tirzepatide) for weight management… read more.
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress in Australia. The results showed… read more.
Bristol Myers Squibb presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is… read more.
A supplemental New Drug Application for approval of Zegfrovy (sunvozertinib) in the 1st-line setting has been accepted by the FDA, supported by positive results from the global WU-KONG28… read more.
The National Institute for Health and Care Excellence (NICE) has issued nine Technology Appraisal decisions in August 2026, comprising five positive first recommendations, one updated positive recommendation, and… read more.
Immedica announces that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to pegzilarginase for the treatment of arginase 1 deficiency (ARG1-D), a… read more.
Egetis Therapeutics AB announced that its partner Fujimoto Pharmaceutical Corporation, which has an exclusive license agreement to develop and commercialize Emcitate (tiratricol) for the treatment of MCT8 deficiency… read more.
NICE (UK) is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma in adults after 2… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
